Overview

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Status:
Recruiting
Trial end date:
2027-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Phase:
Phase 1
Details
Lead Sponsor:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Treatments:
Cyclophosphamide
Fludarabine